Evidence map›Paper›PMID 38357395›Full record

ArticleThe Lancet regional health. Western Pacific2024

Effectiveness of one and two doses of ivermectin mass drug administration in reducing the prevalence and intensity of soil-transmitted helminth (STH) infections in Western Province, Solomon Islands: a cluster-randomised, before-after analysis.

Brandon Le, Naomi E Clarke, Sze Fui Hii, Aisling Byrne, Alam Khattak, Susanna Lake, Erika Lazu, Salote Wickham, Handan Wand, Nick Olsen and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Brandon LeThe Kirby Institute, University of New South Wales, Sydney, Australia.
Naomi E ClarkeThe Kirby Institute, University of New South Wales, Sydney, Australia.
Sze Fui HiiThe University of Melbourne, Melbourne, Australia.
Aisling ByrneThe Kirby Institute, University of New South Wales, Sydney, Australia.
Alam KhattakThe Kirby Institute, University of New South Wales, Sydney, Australia.
Susanna LakeMurdoch Children's Research Institute, Melbourne, Australia.
Erika LazuGizo Hospital, Gizo, Solomon Islands.
Salote WickhamGizo Hospital, Gizo, Solomon Islands.
Handan WandThe Kirby Institute, University of New South Wales, Sydney, Australia.
Nick OlsenStats Central, University of New South Wales, Sydney, Australia.
Patsy A Zendejas-HerediaThe University of Melbourne, Melbourne, Australia.
Oliver SokanaMinistry of Health & Medical Services, Honiara, Solomon Islands.
Lucia RomaniThe Kirby Institute, University of New South Wales, Sydney, Australia.
Daniel EngelmanMurdoch Children's Research Institute, Melbourne, Australia.
Titus NasiMinistry of Health & Medical Services, Honiara, Solomon Islands.
Dickson BoaraGizo Hospital, Gizo, Solomon Islands.
John KaldorThe Kirby Institute, University of New South Wales, Sydney, Australia.
Andrew SteerMurdoch Children's Research Institute, Melbourne, Australia.
Rebecca TraubThe University of Melbourne, Melbourne, Australia.
Susana Vaz NeryThe Kirby Institute, University of New South Wales, Sydney, Australia.
UNSW Sydney · AUMurdoch Children's Research Institute · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ivermectin mass drug administration (MDA) is effective for controlling onchocerciasis and scabies, with evidence supporting its role in some species of soil-transmitted helminth (STH) infections. In the context of RISE, a cluster-randomised trial for scabies, this study evaluated the effectiveness of ivermectin MDA in reducing STH burden in the Western Province of Solomon Islands. Methods: Twenty villages were randomised 1:1 to receive ivermectin MDA as one dose (IVM-1) or two doses (IVM-2) for scabies. The effectiveness of one and two doses in reducing STH prevalence and intensity was evaluated before (May 2019) and 21 months after (February 2021) MDA in May 2019. All residents aged 12 months or older in the study villages were eligible to participate and provide stool specimens. Species-specific STH infection and intensity were assessed using quantitative PCR. We compared prevalence and intensity of infection between baseline and 21 months in each intervention arm individually using cluster-level analysis (adjusted for clustering) and individual-level analysis (adjusted for sex, age, and clustering). The primary outcomes were the prevalence risk difference (RD) from the cluster-level analysis, and the change in adjusted odds of infection from the individual-level analysis. Secondary outcomes included change in incident rates of mean eggs per gram (epg) of stool from baseline to 21 months, relative risk difference in prevalence and relative change in odds of infection between arms at 21 months. Sex data (male/female) were self-reported. Findings: Overall, STH infection was assessed in 830 participants from 18 villages at baseline and 1172 from 20 villages at follow-up. Females represented 58% (n = 478) of the sample at baseline and 59% (n = 690) at follow-up. We observed a reduction in Interpretation: Our study highlights the long-term benefits of ivermectin MDA in reducing the burden of Funding: The National Health and Medical Research Council of Australia.

Indexed as

IvermectinMass drug administrationPreventive chemotherapySoil-transmitted helminths

Identifiers

PMID38357395
PMCPMC10865046
OpenAlexW4388264540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.